The Multiple Myeloma Research Foundation (MMRF) Announces the First Patient Enrolled in its Horizon Clinical Trials Program to Accelerate the Identification of Optimal Treatment Strategies for Multiple MyelomaThe Horizon Clinical Trials Program uses an adaptive platform designed to test multiple therapies simultaneously to determine the best combination, sequence, and duration of therapy to improve patient outcomes
Multiple Myeloma Research Foundation (MMRF) Presents New Data from Multiple Myeloma Research Programs at the 21st International Myeloma Society Annual MeetingNORWALK, Conn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research Foundation (MMRF) announced today new data from two posters and two oral presentations to be shared at the 21st International Myeloma Society (IMS) Annual Meeting, being held in Rio De Janeiro, Brazil, September 25-28, 2024.
Multiple Myeloma Research Foundation (MMRF) Announces New Publication on CoMMpass℠ Study in Nature Genetics Defining Distinct Subtypes of Multiple Myeloma and High-Risk Genetic MarkersNORWALK, Conn., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research Foundation (MMRF) announced today a new publication on the CoMMpassSM study in Nature Genetics that defines distinct subtypes and identifies high-risk genetic markers of multiple myeloma. These CoMMpass data represent the largest and most complete clinical and molecular dataset in multiple myeloma.
The Multiple Myeloma Research Foundation Announces $21M Grant Program to Support Multicenter Translational Research Networks
The Multiple Myeloma Research Foundation (MMRF) announced today the recipients of three $7 million MMRF Myeloma Accelerator Challenge (MAC) Program Grants totaling $21 million. Each of these three-year multicenter translational projects aim to foster collaboration and advance compelling hypotheses that are ready for rapid testing in clinical trials, a critical step in the MMRF’s urgent pursuit of a cure for each and every myeloma patient.
MMRF Research Programs Expand Understanding of the Biology of Multiple Myeloma and Patient-Reported Outcomes in New Data Featured at the 20th IMS Annual Meeting
The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠ datasets will be featured in an oral abstract and poster presentations at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece, September 27-30, 2023. Topics include:
Moving Mountains for Multiple Myeloma® Program to Trek Through Alaska, July 23-29
As part of the Moving Mountains for Multiple Myeloma® (MM4MM) program, a team of 11 intrepid individuals will take an epic journey hiking through the mountainous region outside of Anchorage, AK, from July 23-29, in support of the more than 35,000 patients diagnosed with multiple myeloma annually in the United States.
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
Nectin Therapeutics, a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088, Nectin’s first-in-class lead immunotherapy drug candidate, for the treatment of multiple myeloma.
MMRF Programs Drive Advances in Cancer Research at 64th American Society of Hematology (ASH) Annual Meeting
Today, the Multiple Myeloma Research Foundation (MMRF) announced that new insights related to novel targets, risk assessment, and potential improved treatment approaches generated through its landmark CoMMpass℠ Study and MyDRUG℠ platform trial will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana from December 10 – 13, 2022.
The Multiple Myeloma Research Foundation (MMRF) Names George Mulligan, Ph.D., Chief Scientific Officer
The Multiple Myeloma Research Foundation (MMRF) has appointed George Mulligan, Ph.D., as its new Chief Scientific Officer effective immediately. In this role, Dr. Mulligan will lead the development, execution, and communication of the MMRF’s overall research strategy to drive clinically meaningful scientific advances for myeloma patients.
Kathy Giusti, MMRF Founder & Chief Mission Officer, named recipient of American Association for Cancer Research Distinguished Public Service Award
Kathy Giusti, MBA, Founder and Chief Mission Officer of the Multiple Myeloma Research Foundation and Co-Chair the Harvard Business School Kraft Precision Medicine Accelerator; Nancy P. Pelosi (D-California), Speaker of the U.S. House of Representatives; and Charles L. Sawyers, MD, FAACR, world-renowned cancer researcher and AACR Past President, received their awards virtually at the AACR Annual Meeting 2021 on April 11, 2021. The American Association for Cancer Research (AACR) presented Distinguished Public Service Awards to three individuals whose extraordinary work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, advocacy, and funding for cancer research.
